Keisuke Oyama, Hisataka Ogawa*, Mao Osaki, Syugo Kono, Makoto Hasegawa, Yusuke Izutani, Kazuya Kato, Seiya Kurimasa, Himura Hoshi, Nobuyoshi Ohara, Yuichiro Miyake, Jota Mikami, Sakae Maeda, Shin Nakahira, Yoichi Makari, Ken Nakata, Junya Fujita and Hiroki Ohzato
Department of Surgery, Sakai City Medical Center, JapanFulltext PDF
Sarcopenia is defined as age-related muscle loss that contributes to weakening muscle strength and limited physical performance. It is also reported as an independent prognostic factor in patients with gastrointestinal tract cancer. Computed Tomography (CT) scan has been the gold standard for assessing skeletal muscle mass, despite its drawbacks, including the long-time required, high cost, and radiation exposure. The present study aimed to validate bioelectrical impedance analysis, with the InBody 770 tool, for assessing skeletal muscle mass. In our hospital, we have started sarcopenia screening using InBody 770 for patients with gastrointestinal cancer since 2018. A total of 112 consecutive patients that had undergone gastrointestinal tract cancer surgery, between May and Dec 2018, received preoperative skeletal muscle mass measurements with both CT scan and InBody 770. The correlation between Skeletal Muscle Mass Index (SMI) measured by InBody 770 and the psoas major muscle area index (L3 level) and the psoas major muscle volume index was investigated using image analysis software (SYNAPSE VINCENT). The SMI, psoas muscle area index, and psoas muscle volume index were: 6.3 ± 1.1 kg/m2, 4.4 ± 1.4 cm2/m2 and 90.3 ± 30 cm3/m2. The SMI was correlated more strongly with the psoas muscle volume index (r=0.62) than with the psoas muscle area index (r=0.58). Our results demonstrated that the InBody 770 could act as a substitute for CT scan, in measuring skeletal muscle mass.
Oyama K, Ogawa H, Osaki M, Kono S, Hasegawa M, Izutani Y, et al. Validation of InBody 770 as a Tool for Assessing Skeletal Muscle Mass. Clin Surg. 2019; 4: 2637.